J R Brown

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi The treatment of relapsed refractory chronic lymphocytic leukemia
    Jennifer R Brown
    Harvard Medical School and CLL Center, Dana Farber Cancer Institute, Boston, MA, USA
    Hematology Am Soc Hematol Educ Program 2011:110-8. 2011
  2. ncbi The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients
    J R Brown
    Department of Medicine, Massachusetts General Hospital, Boston 02114, USA
    Thromb Haemost 85:979-85. 2001
  3. ncbi Challenges in the development of platelet growth factors: low expectations for low counts
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Hematol Rep 1:110-8. 2002
  4. ncbi Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 143:361-8. 2008
  5. ncbi Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 51:1382-5. 2010
  6. ncbi A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas
    Jennifer R Brown
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 145:741-8. 2009
  7. ncbi Chronic lymphocytic leukemia: a niche for flavopiridol?
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:3971-3. 2005
  8. ncbi Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
  9. ncbi Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
  10. ncbi Inherited predisposition to chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Expert Rev Hematol 1:51-61. 2008

Collaborators

Detail Information

Publications23

  1. ncbi The treatment of relapsed refractory chronic lymphocytic leukemia
    Jennifer R Brown
    Harvard Medical School and CLL Center, Dana Farber Cancer Institute, Boston, MA, USA
    Hematology Am Soc Hematol Educ Program 2011:110-8. 2011
    ..This review discusses the activity of available and novel therapeutics in fludarabine-refractory or fludarabine-resistant CLL as well as recently updated data on alloSCT in CLL...
  2. ncbi The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients
    J R Brown
    Department of Medicine, Massachusetts General Hospital, Boston 02114, USA
    Thromb Haemost 85:979-85. 2001
    ..Given the increasing number of studies establishing the clinical efficacy of low molecular weight heparins as antithrombotic agents, these results suggest that TFPI may not be a major contributor to the antithrombotic effect of heparin...
  3. ncbi Challenges in the development of platelet growth factors: low expectations for low counts
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Hematol Rep 1:110-8. 2002
    ....
  4. ncbi Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 143:361-8. 2008
    ..026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden...
  5. ncbi Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 51:1382-5. 2010
    ..As laboratory efforts start to provide more insight into the mechanisms of antitumor efficacy and tumor flare, rational strategies for combination therapy will soon follow...
  6. ncbi A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas
    Jennifer R Brown
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 145:741-8. 2009
    ....
  7. ncbi Chronic lymphocytic leukemia: a niche for flavopiridol?
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:3971-3. 2005
  8. ncbi Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
    ....
  9. ncbi Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
    ..We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression...
  10. ncbi Inherited predisposition to chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Expert Rev Hematol 1:51-61. 2008
    ..In the coming years, the application of systematic genomics approaches to familial CLL should, hopefully, lead to the identification of novel loci involved in the disease...
  11. ncbi Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  12. ncbi Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:1057-65. 2007
    ..99-8.8, P=.0002). No significant predictors of overall survival were identified. These results at 12-year follow-up suggest that a subset of follicular lymphoma patients can experience prolonged survival with ABMT in first remission...
  13. ncbi Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma
    Bryan E Figueroa
    Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA, USA
    J Clin Oncol 22:4228-30. 2004
  14. ncbi Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Am J Clin Pathol 121:701-8. 2004
    ..These observations imply that, similar to the observations in B-cell NHLs occurring with HD, a subset of synchronous and metachronous T-cell NHLs and HD may be related clonally...
  15. ncbi Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Leuk Lymphoma 45:315-20. 2004
    ..003). Outcomes of autologous BMT in patients with disseminated marginal zone NHL are similar to those in follicular NHL, and suggest that certain patients may experience prolonged disease-free survival...
  16. ncbi Fos family members induce cell cycle entry by activating cyclin D1
    J R Brown
    Division of Neuroscience, Children s Hospital, Boston, Massachusetts 02115, USA
    Mol Cell Biol 18:5609-19. 1998
    ....
  17. ncbi Pseudohyperkalemia in chronic lymphocytic leukemia
    Kathryn J Ruddy
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 26:2781-2. 2008
  18. ncbi Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
    Victoria Del Gaizo Moore
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:112-21. 2007
    ..Indeed, activator BH3-only occupation of BCL2 may prime cancer cells for death, offering a potential explanation for the marked chemosensitivity of certain cancers that express abundant BCL2, such as CLL and follicular lymphoma...
  19. ncbi Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:2208-14. 2005
    ..Although the incidence of MDS/AML starts to plateau, the incidence of solid tumors continues to rise. Second malignancies are responsible for a significant fraction of overall mortality following ABMT...
  20. ncbi Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia
    Akinori Yoda
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 107:252-7. 2010
    ..Together, these findings implicate CRLF2 as an important factor in B-ALL with diagnostic, prognostic, and therapeutic implications...
  21. ncbi Clinical mimics of lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Oncologist 9:406-16. 2004
    ..Physicians need to be aware of all of these disorders when evaluating suspicious lymphadenopathy, while also considering the more common lymphomas and leukemias...
  22. ncbi AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter
    Yi-Bin Chen
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:3176-8. 2007
  23. ncbi Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...